Tolerx, Inc., a world leader in immunology, has a portfolio of innovative, first-in-class drug candidates to treat type 1 diabetes, other autoimmune diseases, and cancer by normalizing immune responses. The company’s pipeline includes its lead candidate, otelixizumab, a targeted T cell immunotherapy in Phase 3 development for type 1 diabetes, for which Tolerx is partnered with GlaxoSmithKline. A second clinical product candidate, TRX518, is a targeted T cell immunotherapy in Phase 1 development for cancer. TRX1, a third immunotherapy candidate, is an anti-CD4 antibody that has been clinically evaluated for the treatment of aberrant or untoward immune responses. The company also has two preclinical candidates, TRX585 and TRX385, which enhance immune responses and are being evaluated for potential benefit in the treatment of cancer and chronic viral infections. Tolerx is a privately held company headquartered in Cambridge, MA USA.
Looking for a particular Tolerx, Inc. employee's phone or email?
Tolerx, Inc. Questions
The Tolerx, Inc. annual revenue was $8.8 million in 2026.
Mary Matthew is the Director, Regulatory Affairs of Tolerx, Inc..
4 people are employed at Tolerx, Inc..
Tolerx, Inc. is based in Cambridge, Massachusetts.
The NAICS codes for Tolerx, Inc. are [32, 32541, 3254, 325].
The SIC codes for Tolerx, Inc. are [28, 283, 2834].
Top Tolerx, Inc. Employees
-
Mary Matthew
Director, Regulatory Affairs at Tolerx, Inc.
Berlin, MA, US13 -
Tracey Dembro
Executive Assistant to CEO at Tolerx, Inc.
Cambridge, MA, US13 -
Adam Oshea
Scientist at Tolerx, Inc.
Cambridge, MA, US13 -
David Crowell
Sr. Systems Engineer at Tolerx, Inc.
Boston, MA, US13
Related Companies
